Quick Answer
SAB Biotherapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $0.00 for the year ending 2025.
- SAB Biotherapeutics, Inc. showed a decrease of -100.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from SAB Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $16.93 million | Q2 2021: $18.21 million | Q3 2021: $14.68 million | Q1 2022: $11.80 million | Q2 2022: $6.35 million | Q3 2022: $3.59 million | Q1 2023: $581.1 thousand | Q2 2023: $85.5 thousand | Q3 2023: $1.27 million | Q1 2024: $944.6 thousand | Q2 2024: $263.1 thousand.
- Over the full 6 years of available data (2020 to 2025), SAB Biotherapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 100.0%.
- Historical annual values: Fiscal year 2025: $0.00 | Fiscal year 2024: $1.32 million | Fiscal year 2023: $2.24 million | Fiscal year 2022: $23.90 million | Fiscal year 2021: $60.88 million | Fiscal year 2020: $55.24 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: